Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) shares saw unusually-strong trading volume on Monday . Approximately 414,484 shares traded hands during trading, an increase of 10% from the previous session’s volume of 377,043 shares.The stock last traded at $172.14 and had previously closed at $173.03.

A number of analysts have recently commented on ICPT shares. Wells Fargo & Co. upgraded Intercept Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Tuesday, April 5th. Robert W. Baird reiterated a “buy” rating and set a $32.00 target price on shares of Intercept Pharmaceuticals in a research report on Tuesday, April 5th. FBR & Co restated a “hold” rating and issued a $192.00 price target on shares of Intercept Pharmaceuticals in a research report on Tuesday, April 5th. Vetr cut Intercept Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $164.14 price target on the stock. in a research report on Wednesday, April 6th. Finally, Leerink Swann restated a “hold” rating and issued a $144.00 price target on shares of Intercept Pharmaceuticals in a research report on Wednesday, April 6th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and eleven have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $187.98.

The stock’s 50 day moving average price is $149.65 and its 200-day moving average price is $135.54. The company’s market cap is $4.17 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($5.17) earnings per share for the quarter, missing the consensus estimate of ($3.60) by $1.57. During the same period in the previous year, the business posted ($1.78) EPS. On average, equities research analysts forecast that Intercept Pharmaceuticals Inc. will post ($16.94) earnings per share for the current year.

In related news, CEO Mark Pruzanski sold 714 shares of the stock in a transaction dated Tuesday, July 5th. The shares were sold at an average price of $145.11, for a total transaction of $103,608.54. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Lisa Bright sold 251 shares of the stock in a transaction dated Wednesday, May 25th. The stock was sold at an average price of $137.50, for a total transaction of $34,512.50. Following the sale, the insider now owns 18,855 shares in the company, valued at approximately $2,592,562.50. The disclosure for this sale can be found here.

A number of large investors have added to or reduced their stakes in the company. Rhumbline Advisers raised its stake in Intercept Pharmaceuticals by 0.7% in the fourth quarter. Rhumbline Advisers now owns 15,849 shares of the biopharmaceutical company’s stock valued at $2,367,000 after buying an additional 109 shares during the period. New York State Common Retirement Fund raised its stake in shares of Intercept Pharmaceuticals by 2.2% in the fourth quarter. New York State Common Retirement Fund now owns 37,400 shares of the biopharmaceutical company’s stock valued at $5,586,000 after buying an additional 800 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Intercept Pharmaceuticals by 1.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 36,610 shares of the biopharmaceutical company’s stock valued at $5,468,000 after buying an additional 578 shares during the last quarter. Finally, BlackRock Advisors LLC raised its stake in shares of Intercept Pharmaceuticals by 5.4% in the fourth quarter. BlackRock Advisors LLC now owns 125,274 shares of the biopharmaceutical company’s stock valued at $18,710,000 after buying an additional 6,461 shares during the last quarter.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.